DDInter1137 DDInter1652
Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Medroxyprogesterone acetate {u} (Compound) resembles {v} (Compound) Medrysone
Medroxyprogesterone acetate {u} (Compound) resembles {v} (Compound) Hydrocortamate
Medroxyprogesterone acetate {u} (Compound) treats {v} (Disease) uterine cancer
Medroxyprogesterone acetate {u} (Compound) binds {v} (Gene) CYP3A4
Medroxyprogesterone acetate {u} (Compound) upregulates {v} (Gene) SPAG4
Medroxyprogesterone acetate {u} (Compound) palliates {v} (Disease) breast cancer
Medroxyprogesterone acetate {u} (Compound) is included by {v} (Pharmacologic Class) Progesterone Congeners
Medroxyprogesterone acetate {u} (Compound) downregulates {v} (Gene) USP22
Medroxyprogesterone acetate {u} (Compound) causes {v} (Side Effect) Palpitations
Medroxyprogesterone acetate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delavirdine
Medroxyprogesterone acetate (Compound) resembles Medrysone (Compound)
Medroxyprogesterone acetate (Compound) resembles Hydrocortamate (Compound)
Medroxyprogesterone acetate (Compound) treats uterine cancer (Disease)
Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene)
Medroxyprogesterone acetate (Compound) upregulates SPAG4 (Gene)
Medroxyprogesterone acetate (Compound) palliates breast cancer (Disease)
Medroxyprogesterone acetate (Compound) is included by Progesterone Congeners (Pharmacologic Class)
Medroxyprogesterone acetate (Compound) downregulates USP22 (Gene)
Medroxyprogesterone acetate (Compound) causes Palpitations (Side Effect)
Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Delavirdine